N-ethoxyethyl-N-ethylbenzylamine | 916851-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-ethoxyethyl-N-ethylbenzylamine
• 英文别名: N-benzyl-2-ethoxy-N-ethylethanamine
• CAS: 916851-36-0
• 化学式: C₁₃H₂₁NO
• 分子量: 207.316
• InChiKey: VTNDRXIZKBPYBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-乙基苄胺 、 2-溴乙基乙基醚 以 乙醇 为溶剂， 以BnEE (12.79 g, 61.69 mmol, yield 61%) was obtained as a pale yellow clear liquid的产率得到N-ethoxyethyl-N-ethylbenzylamine
  参考文献：
  名称：

  PROCESS FOR PRODUCING TRICYCLIC KETONE

  摘要：

  为了通过实用的全合成方法高效地合成伊立替康盐酸盐和多种喜树碱衍生物的起始化合物CPT，本发明提供了一种有效制备与喜树碱（CPT）骨架的CDE环部分相应的三环酮的方法。

  公开号：

  US20120041204A1

文献信息

• Process for producing tricyclic ketone
  申请人：Nishiyama Hiroyuki

  公开号：US20090023927A1

  公开（公告）日：2009-01-22

  In order to efficiently supply CPT, which is a starting compound of irinotecan hydrochloride and a variety of camptothecin derivatives, by a practical total synthesis, the invention provides a means of efficiently preparing a tricyclic ketone that corresponds to a CDE ring moiety of a camptothecin (CPT) skeleton.

  为了通过实际的全合成高效地供应伊立替康盐酸盐的起始化合物CPT和各种喜树碱衍生物，本发明提供了一种有效制备对应于喜树碱（CPT）骨架中的CDE环部分的三环酮的方法。
• Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
  申请人：Molteni Valentina

  公开号：US20070149538A1

  公开（公告）日：2007-06-28

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。本文还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20090264649A1

  公开（公告）日：2009-10-22

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了一些包括二芳基胺结构特征的化合物。还描述了制备这些化合物的方法，利用这些化合物调节c-kit受体活性的方法，以及包含这些化合物的药物组合物和药物。本文还描述了使用这些化合物、药物组合物和药物来治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的疾病或症状的方法。
• 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Chianelli Donatella

  公开号：US20110053952A1

  公开（公告）日：2011-03-03

  The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-raf or b-raf kinases.

  本发明提供了式(I)的化合物及其制药组合物，它们可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调的激酶活性相关的疾病或症状的方法。在某些实施例中，本发明提供使用这些化合物治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、Abl、BCR-Abl、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-RAf或b-RAf激酶异常活化的疾病或症状的方法。
• US7563894B2
  申请人：——

  公开号：US7563894B2

  公开（公告）日：2009-07-21